TSE:3349Consumer Retailing
COSMOS Pharmaceutical (TSE:3349) Margin Improvement Challenges Valuation Concerns In Q2 2026 Earnings
COSMOS Pharmaceutical (TSE:3349) has released its Q2 2026 scorecard, reporting revenue of ¥264.8b and basic EPS of ¥81.72. Trailing twelve month figures show ¥1.0t of revenue and EPS of ¥393.63. The company’s quarterly revenue has moved from ¥244.1b in Q2 2025 to ¥264.8b in Q2 2026, with basic EPS over that span ranging from ¥79.30 to ¥108.95 and trailing twelve month EPS rising from ¥344.38 to ¥393.63, setting this release against a backdrop of gradually firmer margins.
See our full analysis...